Neuren Pharmaceuticals (ASX:NEU) Total Liabilities: A$4.41 Mil (As of Dec. 2025)

What is Neuren Pharmaceuticals Total Liabilities?

Neuren Pharmaceuticals ASX:NEU -3.68% 54 Total Liabilities is A$4.41 Mil as of Dec. 2025. GuruFocus rates ASX:NEU with a GF Score™ of 54/100 and a GF Value™ of A$7.13 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Neuren Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 was A$4.41 Mil.

Neuren Pharmaceuticals's quarterly Total Liabilities declined from Dec. 2024 (A$45.80 Mil) to Jun. 2025 (A$7.98 Mil) and declined from Jun. 2025 (A$7.98 Mil) to Dec. 2025 (A$4.41 Mil).

Neuren Pharmaceuticals's annual Total Liabilities increased from Dec. 2023 (A$42.76 Mil) to Dec. 2024 (A$45.80 Mil) but then declined from Dec. 2024 (A$45.80 Mil) to Dec. 2025 (A$4.41 Mil).

Neuren Pharmaceuticals Total Liabilities Related Terms

Neuren Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Neuren Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuren Pharmaceuticals Total Liabilities Chart

Neuren Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

0.80

1.68

42.76

45.80

4.41

Neuren Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Total Liabilities	Get a 7-Day Free Trial															42.76	9.00	45.80	7.98	4.41

54GF Score

Neuren Pharmaceuticals Ltd ASX:NEU

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Neuren Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Neuren Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.337	+	(0	+	4.9960036108132E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0.068	+	0)
	=	4.41

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	342.859	-	338.454
	=	4.40

Neuren Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.337	+	(0	+	4.9960036108132E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0.068	+	0)
	=	4.41

Total Liabilities	=	Total Assets (Q: Dec. 2025 )	-	Total Equity (Q: Dec. 2025 )
	=	342.859	-	338.454
	=	4.40

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of A$4.41 Mil mean?

Neuren Pharmaceuticals (ASX:NEU) has a Total Liabilities of A$4.41 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Neuren Pharmaceuticals and its competitors.

Is Neuren Pharmaceuticals' Total Liabilities too high?

Neuren Pharmaceuticals' current Total Liabilities is A$4.41 Mil. Overall, Neuren Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Neuren Pharmaceuticals' Total Liabilities compare to VRTX and REGN?

Neuren Pharmaceuticals' Total Liabilities of A$4.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Neuren Pharmaceuticals and its competitors. Neuren Pharmaceuticals's current Total Liabilities is A$4.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Neuren Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Neuren Pharmaceuticals (ASX:NEU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$7.13, compared to a current price of A$17.00 — trading 138.4% above its estimated fair value. The current Total Liabilities is A$4.41 Mil. Neuren Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Neuren Pharmaceuticals (ASX:NEU), the current Total Liabilities is A$4.41 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuren Pharmaceuticals (ASX:NEU) Overvalued in 2026?

Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued. The current stock price of A$17.00 is trading 138.4% above its estimated GF Value™ of A$7.13. GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ASX:NEU:

Total Liabilities: A$4.41 Mil
GF Value™: A$7.13 vs. price of A$17.00 (138.4% above fair value)
GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the ASX:NEU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuren Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ASX:PYC ASX:CU6 ASX:MSB ASX:CUV ASX:RAC ASX:TTX ASX:SPL ASX:OCC ASX:ATH ASX:ACW VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges NURPF:USA NK9:Germany

Address 117 Camberwell Road, Suite 1.01, Hawthorn East, Melbourne, VIC, AUS, 3123

Website https://www.neurenpharma.com

Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.

54GF Score

Get the complete analysis for ASX:NEU

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$17.00

Price

A$7.13

GF Value

View ASX:NEU Analysis

See Total Liabilities data for all stocks →